adrenomyeloneuropathy


Also found in: Dictionary, Acronyms, Wikipedia.
Related to adrenomyeloneuropathy: adrenoleukodystrophy

a·dre·no·my·e·lo·neu·rop·a·thy

(ă-drē'nō-mī'ĕ-lō-nū-rop'ă-thē),
A disorder of men, consisting of long-standing adrenal insufficiency, hypogonadism, progressive myelopathy, peripheral neuropathy, and sphincter disturbances; considered a variant of adrenoleukodystrophy.
[adreno- + G. myelos, medulla, + neuron, nerve, + pathos, suffering]

adrenomyeloneuropathy

/adre·no·my·elo·neu·rop·a·thy/ (-mi″ĕ-lo-ndbobr-rop´ah-the) a hereditary condition related to adrenoleukodystrophy but including spinal cord degeneration and peripheral neuropathy.

adrenomyeloneuropathy

An X-linked recessive disorder characterised by a non-inflammatory distal axonopathy involving mainly spinal cord, long tracts and to a lesser extent, peripheral nerves. It is a nervous system manifestation of adrenoleukodystrophy.

Clinical findings
Slowly progressive diplegia; peripheral neuropathy with or without primary adrenal failure, as well as primary testicular failure; red-green colour blindness; and depression. It affects 1 in 20–100,000 males, most commonly as cerebral adrenoleukodystrophy in childhood or adrenomyeloneuropathy in adulthood.

ad·re·no·my·e·lo·neu·rop·a·thy

(ă-drē'nō-mī'ĕ-lō-nūr-op'ă-thē)
A disorder of men, consisting of long-standing adrenal insufficiency, hypogonadism, progressive myelopathy, peripheral neuropathy, and sphincter disturbances; considered a variant of adrenoleukodystrophy.
[adreno- + G. myelos, medulla, + neuron, nerve, + pathos, suffering]
References in periodicals archive ?
Mehndiratta MM, Rao KB , Garg s, Pandey Adrenomyeloneuropathy JAPI 2005,53;562-3.
Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans.
19, 2011 /PRNewswire/ -- Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV/AIDS), Adrenomyeloneuropathy (AMN) and Pain, announced today that its wholly-owned subsidiary, ReceptoPharm, has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing the composition of matter and the use of neurotoxins for the treatment of Multiple Sclerosis (MS).
ReceptoPharm is preparing for Phase IIb/IIIa clinical studies for Adrenomyeloneuropathy (AMN) as well as Phase IIa studies for MS and HIV/AIDS.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that sales of its recently launched over-the-counter pain reliever, Cobroxin, totaled $583,955 for the fourth quarter ending December 31, 2009.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has successfully submitted the final packaging and labeling to the Food and Drug Administration (FDA) to begin selling Nyloxin OTC, an over-the-counter treatment for moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, a prescription treatment for severe (Stage 3) chronic pain.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company's treatments for chronic pain.
OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever.